Physician

Felix G. Rabito, M.D.

According to 2025 Medicare claims, Felix Rabito, M.D. (NPI: 1619939410) practices gastroenterology in the Slidell-Mandeville-Covington, LA market, with the plurality of this provider's patient population coming from St. Tammany, LA. This provider's primary affiliated billing organization is TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC (NPI: 1295428415; TIN: 752005254) and primary practice location at 70433-7244.

Rabito's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 450 traditional Medicare patients, billed 5,832 HCPCS/CPT codes, and received $176,489 in Medicare payments. The top billing code was 45385 (Removal of polyps or growths of large bowel using an endoscope with mechanical snare). Part D data shows 1,340 prescription claims across 448 beneficiaries totaling $476,187 in drug costs, led by Rezdiffra (Resmetirom). 2019 DME data shows 36 claims. Open Payments data shows 208 records totaling $9,309. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $101,161 to $176,489. In contrast, Part D prescription costs have moved from a higher plateau to a lower plateau, from $1,287,974 to $476,187. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	463	1,045	$101,161
2016	494	1,025	$101,658
2017	496	1,115	$103,325
2018	502	1,486	$126,069
2019	511	1,686	$127,987
2020	421	1,447	$110,387
2021	478	1,530	$123,571
2022	445	1,651	$104,019
2023	486	4,570	$170,825
2024	450	5,832	$176,489

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	482	2,055	$1,287,974
2016	503	2,006	$961,888
2017	477	1,973	$757,356
2018	432	1,668	$1,068,102
2019	436	1,659	$809,463
2020	512	1,886	$517,993
2021	639	1,926	$476,342
2022	396	1,251	$285,099
2023	557	1,429	$347,604
2024	448	1,340	$476,187

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	24	$664
2016	N/R	N/R	N/R
2017	N/R	64	$32,657
2018	N/R	179	$82,115
2019	N/R	36	$20,437
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
45385	Removal of polyps or growths of large bowel using an endoscope with mechanical snare	81	84	$192
45380	Biopsy of large bowel using a flexible endoscope	66	66	$106
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	89	90	$91
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	72	83	$85
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	152	200	$60

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Rezdiffra	Resmetirom	19	570	$74,418
Creon	Lipase/Protease/Amylase	33	873	$66,749
Xifaxan	Rifaximin	12	312	$34,315
Mesalamine	Mesalamine	38	1,574	$24,124
Linzess	Linaclotide	22	720	$12,355

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	207	$9,309	QOL Medical, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$9,501	GastroGPO, LLC

Explore More Providers

FAQ

What Medicare data is available for Felix G. Rabito, M.D.?

Tedicare shows public-source Medicare data for Felix G. Rabito, M.D. (NPI 1619939410), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Felix G. Rabito, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Felix G. Rabito, M.D.?

Felix G. Rabito, M.D. is linked to TEXAS DIGESTIVE DISEASE CONSULTANTS PLLC (billing NPI 1295428415) in the available physician profile data.

Does Felix G. Rabito, M.D. have Open Payments data?

Felix G. Rabito, M.D. has 208 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.